{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T07:00:45Z","timestamp":1772348445426,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02076-3","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T23:14:41Z","timestamp":1743290081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PD-1\/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)"],"prefix":"10.1007","volume":"16","author":[{"given":"Samaneh","family":"Moradi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Sarikhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafid Jihad","family":"Albadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waam Mohammed","family":"Taher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariem","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood Jasem","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niyousha","family":"Vakilzadehian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"52","key":"2076_CR1","doi-asserted-by":"publisher","first-page":"85917","DOI":"10.18632\/oncotarget.13185","volume":"7","author":"H-Y Wang","year":"2016","unstructured":"Wang H-Y, Chang Y-L, Cheng C-C, Chao M-W, Lin S-I, Pan S-L, Hsu C-C, et al. Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget. 2016;7(52):85917\u201328.","journal-title":"Oncotarget"},{"issue":"2","key":"2076_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3727\/096504019X15707883083132","volume":"28","author":"X Weng","year":"2020","unstructured":"Weng X, Luo S, Lin S, Zhong L, Li M, Xin R, Huang P, et al. Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels. Oncol Res. 2020;28(2):117\u201325.","journal-title":"Oncol Res"},{"issue":"6\u20137","key":"2076_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.canrad.2011.07.234","volume":"15","author":"S Rivera","year":"2011","unstructured":"Rivera S, Qu\u00e9ro L, Wong Hee Kam S, Maylin C, Deutsch E, Hennequin C. Targeted therapies and radiation therapy in non-small cell lung cancer. Cancer Radiother. 2011;15(6\u20137):527\u201335.","journal-title":"Cancer Radiother"},{"issue":"6","key":"2076_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1188\/12.ONF.609-616","volume":"39","author":"J Luo","year":"2012","unstructured":"Luo J, Chen YJ, Narsavage GL, Ducatman A. Predictors of survival in patients with non-small cell lung cancer. Oncol Nurs Forum. 2012;39(6):609\u201316.","journal-title":"Oncol Nurs Forum"},{"issue":"1","key":"2076_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2005.08.031","volume":"42","author":"M Tiseo","year":"2006","unstructured":"Tiseo M, Franciosi V, Grossi F, Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? Eur J Cancer. 2006;42(1):8\u201316.","journal-title":"Eur J Cancer"},{"key":"2076_CR6","doi-asserted-by":"publisher","first-page":"1405485","DOI":"10.3389\/fimmu.2024.1405485","volume":"15","author":"D Ibrahim","year":"2024","unstructured":"Ibrahim D, Sim\u00f3 C, Brown EL, Shmuel S, Panikar SS, Benton A, DeWeerd R, et al. PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET. Front Immunol. 2024;15:1405485.","journal-title":"Front Immunol"},{"key":"2076_CR7","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2147\/OTT.S156775","volume":"11","author":"S-X Tan","year":"2018","unstructured":"Tan S-X, Hu R-C, Xia Q, Tan Y-L, Liu J-J, Gan G-X, Wang L-L. The methylation profiles of PRDM promoters in non-small cell lung cancer. OncoTargets Ther. 2018;11:2991\u20133002.","journal-title":"OncoTargets Ther"},{"issue":"4","key":"2076_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2076_CR9","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"issue":"16","key":"2076_CR10","doi-asserted-by":"publisher","first-page":"26281","DOI":"10.18632\/oncotarget.15457","volume":"8","author":"J Du","year":"2017","unstructured":"Du J, Wu X, Tong X, Wang X, Wei J, Yang Y, Chang Z, et al. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. Oncotarget. 2017;8(16):26281.","journal-title":"Oncotarget"},{"issue":"4","key":"2076_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"key":"2076_CR12","doi-asserted-by":"publisher","first-page":"1434078","DOI":"10.3389\/fimmu.2024.1434078","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Kong M, Shen F, Li P, Chen C, Li Y, Li C, et al. Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer. Front Immunol. 2024;15:1434078.","journal-title":"Front Immunol"},{"key":"2076_CR13","doi-asserted-by":"publisher","first-page":"1189953","DOI":"10.3389\/fimmu.2023.1189953","volume":"14","author":"J Lin","year":"2023","unstructured":"Lin J, Fang W, Xiang Z, Wang Q, Cheng H, Chen S, Fang J, et al. Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion. Front Immunol. 2023;14:1189953.","journal-title":"Front Immunol"},{"key":"2076_CR14","doi-asserted-by":"publisher","first-page":"1234894","DOI":"10.3389\/fimmu.2023.1234894","volume":"14","author":"YM Wang","year":"2023","unstructured":"Wang YM, Cai W, Xue QM, Zhang JY, Zhou L, Xiong SY, Deng H. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1234894.","journal-title":"Front Immunol"},{"issue":"1","key":"2076_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2076_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.","journal-title":"Mol Cancer"},{"issue":"3","key":"2076_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"key":"2076_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2019.01.004","volume":"129","author":"YW Koh","year":"2019","unstructured":"Koh YW, Lee SJ, Han JH, Haam S, Jung J, Lee HW. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohistochemistry and RNA sequencing data. Lung Cancer. 2019;129:41\u20137.","journal-title":"Lung Cancer"},{"issue":"5","key":"2076_CR19","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.21037\/jtd.2017.04.55","volume":"9","author":"C Teixid\u00f3","year":"2017","unstructured":"Teixid\u00f3 C, Rosell R. Neutrophils dominate the immune landscape of non-small cell lung cancer. J Thorac Dis. 2017;9(5):E468\u20139.","journal-title":"J Thorac Dis"},{"key":"2076_CR20","doi-asserted-by":"publisher","first-page":"175883592093688","DOI":"10.1177\/1758835920936882","volume":"12","author":"F Zhang","year":"2020","unstructured":"Zhang F, Huang D, Zhao L, Li T, Zhang S, Zhang G, Yuan F, et al. Efficacy and safety of PD-1\/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. Ther Adv Med Oncol. 2020;12:1758835920936882.","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"2076_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625\u201344.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2076_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2076_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"M Alexander","year":"2020","unstructured":"Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198(6):897\u2013907.","journal-title":"Lung"},{"key":"2076_CR24","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.","journal-title":"Nat Rev Dis Primers"},{"key":"2076_CR25","volume-title":"Non small cell lung cancer","author":"SB Clark","year":"2022","unstructured":"Clark SB, Alsubait S. Non small cell lung cancer. Treasure Island: StatPearls Publishing; 2022."},{"issue":"9","key":"2076_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.271","volume":"7","author":"O Klingbeil","year":"2016","unstructured":"Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Cell Death Dis. 2016;7(9): e2365.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2076_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4103\/crst.crst_222_22","volume":"5","author":"M Sharma","year":"2022","unstructured":"Sharma M, Basu DA, Nathany S, Amrith B, Batra U. A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma. Cancer Res Stat Treat. 2022;5(3):507\u201318.","journal-title":"Cancer Res Stat Treat"},{"issue":"19","key":"2076_CR28","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-22-0879","volume":"28","author":"HA Jung","year":"2022","unstructured":"Jung HA, Lim J, Choi Y-L, Lee S-H, Joung J-G, Jeon YJ, Choi JW, et al. Clinical, pathologic, and molecular prognostic factors in patients with early-stage EGFR-mutant NSCLC. Clin Cancer Res. 2022;28(19):4312\u201321.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2076_CR29","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1134\/S1068162024060347","volume":"50","author":"A Shvetsov","year":"2024","unstructured":"Shvetsov A, Semenov A. Covalent epidermal growth factor receptor (EGFR) inhibitors in targeted therapy of drug-resistant non-small cell lung cancer (a review). Russ J Bioorg Chem. 2024;50(6):2283\u2013311.","journal-title":"Russ J Bioorg Chem"},{"issue":"15_suppl","key":"2076_CR30","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/jco.2011.29.15_suppl.2501","volume":"29","author":"D Camidge","year":"2011","unstructured":"Camidge D, Bang Y, Kwak E, Shaw A, Iafrate A, Maki R, Solomon B, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29(15_suppl):2501.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2076_CR31","volume":"10","author":"S Burdett","year":"2016","unstructured":"Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, Pignon JP, et al. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10(10): CD002142-CD.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2076_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.36290\/vnl.2017.159","volume":"63","author":"J Sk\u0159i\u010dkov\u00e1","year":"2018","unstructured":"Sk\u0159i\u010dkov\u00e1 J, Kadlec B, Vencl\u00ed\u010dek O. Non-small cell lung cancer. Vnitr Lek. 2018;63(11):861\u201374.","journal-title":"Vnitr Lek"},{"issue":"30","key":"2076_CR33","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.2174\/13816128113199990343","volume":"19","author":"C Schettino","year":"2013","unstructured":"Schettino C, Bareschino MA, Sacco PC, Maione P, Rossi A, Casaluce F, Sgambato A, et al. New molecular targets in the treatment of NSCLC. Curr Pharm Des. 2013;19(30):5333\u201343.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2076_CR34","first-page":"3415","volume":"15","author":"B Zou","year":"2018","unstructured":"Zou B, Zhou X-L, Lai S-Q, Liu J-C. Notch signaling and non-small cell lung cancer. Oncol Lett. 2018;15(3):3415\u201321.","journal-title":"Oncol Lett"},{"issue":"4","key":"2076_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1188\/08.CJON.587-596","volume":"12","author":"S Walker","year":"2008","unstructured":"Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs. 2008;12(4):587\u201396.","journal-title":"Clin J Oncol Nurs"},{"issue":"15","key":"2076_CR36","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1158\/1078-0432.CCR-15-2998","volume":"22","author":"D Morgensztern","year":"2016","unstructured":"Morgensztern D, Herbst RS. Nivolumab and pembrolizumab for non-small cell lung cancer. Clin Cancer Res. 2016;22(15):3713\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2076_CR37","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.21037\/tcr-20-2815","volume":"10","author":"E Dur\u00e9ndez-S\u00e1ez","year":"2021","unstructured":"Dur\u00e9ndez-S\u00e1ez E, Torres-Martinez S, Calabuig-Fari\u00f1as S, Meri-Abad M, Ferrero-Gimeno M, Camps C. Exosomal microRNAs in non-small cell lung cancer. Transl Cancer Res. 2021;10(6):3128\u201339.","journal-title":"Transl Cancer Res"},{"key":"2076_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.","journal-title":"Health Qual Life Outcomes"},{"issue":"18","key":"2076_CR39","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.3390\/cancers13184537","volume":"13","author":"V Vautrot","year":"2021","unstructured":"Vautrot V, Bentayeb H, Causse S, Garrido C, Gobbo J. Tumor-derived exosomes: hidden players in PD-1\/PD-L1 resistance. Cancers. 2021;13(18):4537.","journal-title":"Cancers"},{"key":"2076_CR40","doi-asserted-by":"publisher","first-page":"110504","DOI":"10.1016\/j.biopha.2020.110504","volume":"129","author":"J Sun","year":"2020","unstructured":"Sun J, Zheng Y, Mamun M, Li X, Chen X, Gao Y. Research progress of PD-1\/PD-L1 immunotherapy in gastrointestinal tumors. Biomed Pharmacother. 2020;129:110504.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2076_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12710","volume":"78","author":"LL Wang","year":"2017","unstructured":"Wang LL, Li ZH, Hu XH, Muyayalo KP, Zhang YH, Liao AH. The roles of the PD-1\/PD-L1 pathway at immunologically privileged sites. Am J Reprod Immunol. 2017;78(2): e12710.","journal-title":"Am J Reprod Immunol"},{"key":"2076_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fphar.2020.00441","volume":"11","author":"L Chocarro de Erauso","year":"2020","unstructured":"Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, et al. Resistance to PD-L1\/PD-1 blockade immunotherapy: a tumor-intrinsic or tumor-extrinsic phenomenon? Front Pharmacol. 2020;11:441.","journal-title":"Front Pharmacol"},{"issue":"23","key":"2076_CR43","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.3390\/ijms21239165","volume":"21","author":"M Chulkina","year":"2020","unstructured":"Chulkina M, Beswick EJ, Pinchuk IV. Role of PD-L1 in gut mucosa tolerance and chronic inflammation. Int J Mol Sci. 2020;21(23):9165.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2076_CR44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5858\/arpa.2016-0361-RA","volume":"141","author":"J Guan","year":"2017","unstructured":"Guan J, Lim KS, Mekhail T, Chang CC. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)\/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med. 2017;141(6):851\u201361.","journal-title":"Arch Pathol Lab Med"},{"key":"2076_CR45","doi-asserted-by":"publisher","first-page":"854967","DOI":"10.3389\/fphar.2022.854967","volume":"13","author":"K Zhang","year":"2022","unstructured":"Zhang K, Kong X, Li Y, Wang Z, Zhang L, Xuan L. PD-1\/PD-L1 inhibitors in patients with preexisting autoimmune diseases. Front Pharmacol. 2022;13:854967.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2076_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1398-9995.2010.02458.x","volume":"66","author":"AK Singh","year":"2011","unstructured":"Singh AK, Stock P, Akbari O. Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy. 2011;66(2):155\u201362.","journal-title":"Allergy"},{"issue":"7","key":"2076_CR47","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3390\/cancers13071714","volume":"13","author":"SJ De Keukeleire","year":"2021","unstructured":"De Keukeleire SJ, Vermassen T, Hilgert E, Creytens D, Ferdinande L, Rottey S. Immuno-oncological biomarkers for squamous cell cancer of the head and neck: current state of the art and future perspectives. Cancers. 2021;13(7):1714.","journal-title":"Cancers"},{"issue":"1","key":"2076_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2076_CR49","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.3747\/co.25.4031","volume":"25","author":"DN Ionescu","year":"2018","unstructured":"Ionescu DN, Downes MR, Christofides A, Tsao MS. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr Oncol. 2018;25(3):e209\u201316.","journal-title":"Curr Oncol"},{"issue":"23","key":"2076_CR50","doi-asserted-by":"publisher","first-page":"19393","DOI":"10.18632\/oncotarget.5107","volume":"6","author":"X Sui","year":"2015","unstructured":"Sui X, Ma J, Han W, Wang X, Fang Y, Li D, Pan H, et al. The anticancer immune response of anti-PD-1\/PD-L1 and the genetic determinants of response to anti-PD-1\/PD-L1 antibodies in cancer patients. Oncotarget. 2015;6(23):19393\u2013404.","journal-title":"Oncotarget"},{"issue":"3","key":"2076_CR51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.7150\/jca.17547","volume":"8","author":"JE Mann","year":"2017","unstructured":"Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, et al. Surveilling the potential for precision medicine-driven PD-1\/PD-L1-targeted therapy in HNSCC. J Cancer. 2017;8(3):332\u201344.","journal-title":"J Cancer"},{"issue":"7","key":"2076_CR52","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964\u201375.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2076_CR53","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3390\/cancers12113173","volume":"12","author":"S Nimmagadda","year":"2020","unstructured":"Nimmagadda S. Quantifying PD-L1 expression to monitor immune checkpoint therapy: opportunities and challenges. Cancers. 2020;12(11):3173.","journal-title":"Cancers"},{"issue":"23","key":"2076_CR54","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.3390\/ijms20235969","volume":"20","author":"TC Hsieh","year":"2019","unstructured":"Hsieh TC, Wu JM. Tumor PD-L1 induction by resveratrol\/piceatannol may function as a search, enhance, and engage (\u201cSEE\u201d) Signal to facilitate the elimination of \u201ccold, non-responsive\u201d low PD-L1-expressing tumors by PD-L1 blockade. Int J Mol Sci. 2019;20(23):5969.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2076_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4132\/jptm.2019.04.24","volume":"53","author":"H Kim","year":"2019","unstructured":"Kim H, Chung J-H. PD-L1 testing in non-small cell lung cancer: past, present, and future. J Pathol Transl Med. 2019;53(4):199\u2013206.","journal-title":"J Pathol Transl Med"},{"issue":"7","key":"2076_CR56","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.21873\/anticanres.12662","volume":"38","author":"M Bassanelli","year":"2018","unstructured":"Bassanelli M, Sioletic S, Martini M, Giacinti S, Viterbo A, Staddon A, Liberati F, et al. Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res. 2018;38(7):3789\u201396.","journal-title":"Anticancer Res"},{"issue":"4","key":"2076_CR57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2076_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-017-0308-6","volume":"22","author":"K Ancevski Hunter","year":"2018","unstructured":"Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 testing in guiding patient selection for PD-1\/PD-L1 inhibitor therapy in lung cancer. Mol Diagn Ther. 2018;22(1):1\u201310.","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"2076_CR59","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.21873\/anticanres.15736","volume":"42","author":"T Shiozawa","year":"2022","unstructured":"Shiozawa T, Numata T, Tamura T, Endo T, Kaburagi T, Yamamoto Y, Yamada H, et al. Prognostic implication of PD-L1 expression on osimertinib treatment for EGFR-mutated non-small cell lung cancer. Anticancer Res. 2022;42(5):2583\u201390.","journal-title":"Anticancer Res"},{"issue":"35","key":"2076_CR60","doi-asserted-by":"publisher","first-page":"58457","DOI":"10.18632\/oncotarget.17022","volume":"8","author":"C Zhou","year":"2017","unstructured":"Zhou C, Tang J, Sun H, Zheng X, Li Z, Sun T, Li J, et al. PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget. 2017;8(35):58457\u201368.","journal-title":"Oncotarget"},{"issue":"1","key":"2076_CR61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13014-020-01696-z","volume":"15","author":"M Vrankar","year":"2020","unstructured":"Vrankar M, Kern I, Stanic K. Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. Radiat Oncol. 2020;15(1):247.","journal-title":"Radiat Oncol"},{"issue":"3","key":"2076_CR62","first-page":"239","volume":"37","author":"H Arak","year":"2021","unstructured":"Arak H, Aytekin A, Canoz O, Ozkan M. Prognostic and predictive significance of PD-L1 expression in non-small cell lung cancer patients: a single-center experience. Turk Patoloji Derg. 2021;37(3):239\u201348.","journal-title":"Turk Patoloji Derg"},{"issue":"8","key":"2076_CR63","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.21037\/tcr.2019.11.08","volume":"8","author":"L Xia","year":"2019","unstructured":"Xia L, Huang H, Xiao H, Wang D, Yang Z. Utilization of combined PD-L1 expression and neutrophil-to-lymphocyte ratio prior to surgery as a prognostic factor in non-small cell lung cancer with brain metastasis. Transl Cancer Res. 2019;8(8):2864\u201377.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"2076_CR64","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41598-018-36096-7","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A, Zhao L, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep. 2019;9(1):566.","journal-title":"Sci Rep"},{"issue":"48","key":"2076_CR65","doi-asserted-by":"publisher","first-page":"83986","DOI":"10.18632\/oncotarget.20233","volume":"8","author":"G Lin","year":"2017","unstructured":"Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, Lin X, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017;8(48):83986\u201394.","journal-title":"Oncotarget"},{"issue":"5","key":"2076_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cllc.2021.03.005","volume":"22","author":"FG Dall'Olio","year":"2021","unstructured":"Dall\u2019Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, et al. PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2021;22(5):423\u201331.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2076_CR67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4149\/neo_2018_170206N77","volume":"65","author":"M Vrankar","year":"2018","unstructured":"Vrankar M, Zwitter M, Kern I, Stanic K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Neoplasma. 2018;65(1):140\u20136.","journal-title":"Neoplasma"},{"issue":"2","key":"2076_CR68","first-page":"753","volume":"38","author":"K Kobayashi","year":"2018","unstructured":"Kobayashi K, Seike M, Zou F, Noro R, Chiba M, Ishikawa A, Kunugi S, et al. Prognostic significance of nsclc and response to EGFR-TKIs of EGFR-mutated NSCLC based on PD-L1 expression. Anticancer Res. 2018;38(2):753\u201362.","journal-title":"Anticancer Res"},{"issue":"4","key":"2076_CR69","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/ijms20040824","volume":"20","author":"K Pawelczyk","year":"2019","unstructured":"Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, Podhorska-Okolow M, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(4):824.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2076_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43046-022-00121-8","volume":"34","author":"AA Bahnassy","year":"2022","unstructured":"Bahnassy AA, Ismail H, Mohanad M, El-Bastawisy A, Yousef HF. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. J Egypt Natl Canc Inst. 2022;34(1):23.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"2","key":"2076_CR71","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","volume":"89","author":"WA Cooper","year":"2015","unstructured":"Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015;89(2):181\u20138.","journal-title":"Lung Cancer"},{"issue":"8","key":"2076_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136023","volume":"10","author":"LH Schmidt","year":"2015","unstructured":"Schmidt LH, K\u00fcmmel A, G\u00f6rlich D, Mohr M, Br\u00f6ckling S, Mikesch JH, Gr\u00fcnewald I, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS ONE. 2015;10(8): e0136023.","journal-title":"PLoS ONE"},{"key":"2076_CR73","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejca.2018.11.020","volume":"107","author":"J von Pawel","year":"2019","unstructured":"von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer. 2019;107:124\u201332.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2076_CR74","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","volume":"16","author":"J Mazieres","year":"2021","unstructured":"Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, Barlesi F, et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol. 2021;16(1):140\u201350.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2076_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","volume":"19","author":"R Bordoni","year":"2018","unstructured":"Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, et al. Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):441-9.e4.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"2076_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001882","volume":"9","author":"D Gandara","year":"2021","unstructured":"Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, et al. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021;9(3): e001882.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2076_CR77","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525\u201331.","journal-title":"Ann Oncol"},{"key":"2076_CR78","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung Cancer. 2019;128:105\u201312.","journal-title":"Lung Cancer"},{"issue":"4","key":"2076_CR79","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/j.cllc.2018.01.004","volume":"19","author":"T Hida","year":"2018","unstructured":"Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, Seto T, et al. Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study. Clin Lung Cancer. 2018;19(4):e405\u201315.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"2076_CR80","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1759-7714.13824","volume":"12","author":"N Furuya","year":"2021","unstructured":"Furuya N, Nishino M, Wakuda K, Ikeda S, Sato T, Ushio R, Tanzawa S, et al. Real-world efficacy of atezolizumab in non-small cell lung cancer: a multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thorac Cancer. 2021;12(5):613\u20138.","journal-title":"Thorac Cancer"},{"issue":"24","key":"2076_CR81","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters S, Gettinger S, Johnson ML, J\u00e4nne PA, Garassino MC, Christoph D, Toh CK, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1\u2013selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781\u20139.","journal-title":"J Clin Oncol"},{"key":"2076_CR82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2018.06.031","volume":"101","author":"L Horn","year":"2018","unstructured":"Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018;101:201\u20139.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2076_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001865","volume":"9","author":"A Ardizzoni","year":"2021","unstructured":"Ardizzoni A, Azevedo S, Rubio-Viqueira B, Rodr\u00edguez-Abreu D, Alatorre-Alexander J, Smit HJM, Yu J, et al. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. J Immunother Cancer. 2021;9(3): e001865.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2076_CR84","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jtho.2018.05.004","volume":"13","author":"DR Spigel","year":"2018","unstructured":"Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1\u2013selected patients with NSCLC. J Thorac Oncol. 2018;13(11):1733\u201342.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2076_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004025","volume":"10","author":"T Seto","year":"2022","unstructured":"Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, et al. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). J Immunother Cancer. 2022;10(2): e004025.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2076_CR86","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2076_CR87","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cllc.2021.07.002","volume":"23","author":"DJ Wong","year":"2022","unstructured":"Wong DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, Zhu J, Zhang X, Cha E. Safety and clinical activity of atezolizumab plus ipilimumab in locally advanced or metastatic non-small cell lung cancer: results from a phase 1b trial. Clin Lung Cancer. 2022;23(3):273\u201381.","journal-title":"Clin Lung Cancer"},{"issue":"24","key":"2076_CR88","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodr\u00edguez-Abreu D, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"2","key":"2076_CR89","first-page":"100104","volume":"2","author":"RN Pillai","year":"2021","unstructured":"Pillai RN, Ramalingam SS, Thayu M, Lorenzini P, Alvarez Arias DA, Moy C, Hutnick N, et al. Daratumumab plus atezolizumab in previously treated advanced or metastatic NSCLC: brief report on a randomized, open-label, phase 1b\/2 study (LUC2001 JNJ-54767414). JTO Clin Res Rep. 2021;2(2):100104.","journal-title":"JTO Clin Res Rep"},{"key":"2076_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.04.001","author":"J Lee","year":"2022","unstructured":"Lee J, Koh J, Kim HK, Hong S, Kim K, Park S, Jung HA, et al. Bevacizumab plus atezolizumab after progression on atezolizumab monotherapy in pretreated patients with NSCLC: an open-label, two-stage, phase 2 trial. J Thorac Oncol. 2022. https:\/\/doi.org\/10.1016\/j.jtho.2022.04.001.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2076_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.941","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, Kang S, Yan M. Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-na\u00efve, stage IV, non-squamous, non-small-cell lung cancer patients: a retrospective analysis. Pharmacol Res Perspect. 2022;10(3): e00941.","journal-title":"Pharmacol Res Perspect"},{"issue":"10308","key":"2076_CR92","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, Luft A, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357.","journal-title":"Lancet"},{"issue":"7","key":"2076_CR93","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"10030","key":"2076_CR94","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837\u201346.","journal-title":"Lancet"},{"issue":"4","key":"2076_CR95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fon-2019-0730","volume":"16","author":"A Vergnenegre","year":"2020","unstructured":"Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, L\u00e9na H, Choua\u00efd C, et al. Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer\u2013VinMetAtezo trial, (GFPC(\u2021) 04-2017). Future Oncol. 2020;16(4):5\u201310.","journal-title":"Future Oncol"},{"key":"2076_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03873-3","author":"B Xu","year":"2022","unstructured":"Xu B, Cheng H, Li K, Lv Y, Zeng X, Liu T, Yu W, et al. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-na\u00efve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. J Cancer Res Clin Oncol. 2022. https:\/\/doi.org\/10.1007\/s00432-021-03873-3.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"2076_CR97","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"2076_CR98","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodr\u00edguez-Abreu D, Hussein M, Soo R, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15(8):1351\u201360.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2076_CR99","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/cas.14817","volume":"112","author":"M Nishio","year":"2021","unstructured":"Nishio M, Saito H, Goto K, Watanabe S, Sueoka-Aragane N, Okuma Y, Kasahara K, et al. IMpower132: atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer Sci. 2021;112(4):1534\u201344.","journal-title":"Cancer Sci"},{"issue":"2","key":"2076_CR100","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","volume":"15","author":"SH Lin","year":"2020","unstructured":"Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, et al. Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. J Thorac Oncol. 2020;15(2):248\u201357.","journal-title":"J Thorac Oncol"},{"key":"2076_CR101","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2018.06.033","volume":"101","author":"SV Liu","year":"2018","unstructured":"Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018;101:114\u201322.","journal-title":"Eur J Cancer"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02076-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02076-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02076-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T02:09:10Z","timestamp":1743473350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02076-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2076"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02076-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}